BiotechTube

Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®

Phase 3Completed
2 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

Apr 8, 2020 → Apr 20, 2022

NCT ID
NCT04268771

About Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®

Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera® is a phase 3 stage product being developed by Dr. Reddy's Laboratories for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04268771. Target conditions include Rheumatoid Arthritis.

What happened to similar drugs?

20 of 20 similar drugs in Rheumatoid Arthritis were approved

Approved (20) Terminated (0) Active (0)
✅Baricitinib + TNF InhibitorEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved
✅TacrolimusAstellas PharmaApproved
✅TacrolimusAstellas PharmaApproved
✅Methotrexate (MTX)EisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04268771Phase 3Completed

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
TilmanoceptNavidea BiopharmaceuticalsPhase 1
11
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
LY2127399Eli LillyPhase 3
32
Baricitinib + TNF InhibitorEli LillyApproved
43
CT-P17 SC AI (adalimumab)CelltrionPhase 3
40
Remsima IV + Remsima SCCelltrionPre-clinical
33
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P47 + EU-approved RoActemraCelltrionPhase 3
40
InfliximabCelltrionPhase 3
40
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
Rituximab, MTX, folic acidCelltrionPhase 1
29
CT-P10 + Rituxan + MabTheraCelltrionPhase 3
40
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)CelltrionPhase 3
36
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 3
40
rituximabCelltrionPhase 1
29